Gerry Kennedy
UK General Counsel, Lonza
Gerry is the UK General Counsel for Lonza, one of the world’s leading suppliers to the pharmaceutical, biotech and specialty ingredients markets. Founded in 1897 in the Swiss Alps, Lonza has more than 40 major manufacturing and R&D facilities and approximately 9,800 employees worldwide, and has its head office in Basel, Switzerland. With over 25 years in-house experience Gerry has worked in a variety of industries from heavy engineering and defence to high-tech, and has spent the last 12 years in the life sciences sector with Lonza. He obtained an MBA from the Cranfield School of Management.
Gerry is based at the Lonza Biologics site in Slough where Lonza focusses on the development and manufacture of monoclonal antibodies, an area that Lonza entered in 1996 following its acquisition of the pioneering Celltech Biologics. Advising Lonza’s Pharma&Biotech sector, Gerry and his team have particular responsibility for concluding development and manufacturing agreements with a wide variety of customers, from large pharma to universities and start-ups, whether at the Slough facility, or at Lonza’s large-scale manufacturing facilities in Spain, Singapore and the US. The team is also responsible for technology licensing agreements relating to the GS gene expression systemTM, and advising on R&D and collaboration agreements.